CTC Alternative Strategies’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

CTC Alternative Strategies’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,010	Closed	-$811K	–	138
2023 Q3	$811K	Buy	7,010 +800	+13%	+$86K	1.53%	17
2023 Q2	$639K	Buy	+6,210	New	+$655K	0.8%	29

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

CTC Alternative Strategies's HZNP Position: Q4 2023 in Review

CTC Alternative Strategies sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 7,010 shares — an estimated $811K sold.

CTC Alternative Strategies first reported a position in HZNP in Q2 2023 and held it in 2 quarters. The position peaked at $811K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

CTC Alternative Strategies reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
CTC Alternative Strategies sold 7,010 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $811K.
CTC Alternative Strategies first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023 and held it in 2 quarters.
CTC Alternative Strategies's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $811K in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on CTC Alternative Strategies's 13F filing for Q4 2023, filed 30 Jan 2024.